Pluristem Therapeutics (NASDAQ:PSTI) posted its earnings results on Sunday. The biotechnology company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.06), Fidelity Earnings reports.
Pluristem Therapeutics stock traded up $0.01 during midday trading on Tuesday, reaching $2.94. The company’s stock had a trading volume of 6,027 shares, compared to its average volume of 489,636. Pluristem Therapeutics has a fifty-two week low of $2.81 and a fifty-two week high of $11.85. The stock’s 50 day simple moving average is $3.26 and its 200 day simple moving average is $4.02.
Separately, Zacks Investment Research raised shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 13th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $9.35.
About Pluristem Therapeutics
Pluristem Therapeutics, Inc is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.